{"id":"nova63035-corticosteroid","safety":{"commonSideEffects":[{"rate":null,"effect":"Local irritation or burning"},{"rate":null,"effect":"Increased intraocular pressure (if ophthalmic)"},{"rate":null,"effect":"Cataract formation (with prolonged use)"}]},"_chembl":{"chemblId":"CHEMBL2104932","moleculeType":"Small molecule","molecularWeight":"398.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a corticosteroid, NOVA63035 exerts anti-inflammatory effects through glucocorticoid receptor activation, reducing the production of pro-inflammatory cytokines and inhibiting immune cell activation. This mechanism makes it suitable for treating inflammatory and allergic conditions. The drug is marketed by Santen SAS, a company focused on ophthalmology and dermatology products, suggesting its primary use is likely in ocular or dermatological inflammatory conditions.","oneSentence":"NOVA63035 is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T05:20:31.216Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory ocular conditions (likely, based on Santen's focus)"}]},"trialDetails":[{"nctId":"NCT00665106","phase":"PHASE1","title":"Safety and Tolerability of NOVA63035 \"Corticosteroid\" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2008-04","conditions":"Diabetic Macular Edema","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20191120","type":"ORIG","sponsor":"CADILA","applicationNumber":"ANDA210198"},{"date":"20160425","type":"ORIG","sponsor":"RISING","applicationNumber":"ANDA090982"},{"date":"20250916","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA090982"},{"date":"20251017","type":"ORIG","sponsor":"ALEMBIC","applicationNumber":"ANDA218601"},{"date":"20140620","type":"SUPPL","sponsor":"BAUSCH AND LOMB","applicationNumber":"NDA021737"},{"date":"20071030","type":"SUPPL","sponsor":"BAUSCH AND LOMB","applicationNumber":"NDA021737"},{"date":"20050408","type":"ORIG","sponsor":"BAUSCH AND LOMB","applicationNumber":"NDA021737"},{"date":"20250404","type":"SUPPL","sponsor":"BAUSCH AND LOMB","applicationNumber":"NDA021737"},{"date":"20101130","type":"SUPPL","sponsor":"BAUSCH AND LOMB","applicationNumber":"NDA021737"},{"date":"20150330","type":"SUPPL","sponsor":"BAUSCH AND LOMB","applicationNumber":"NDA021737"},{"date":"20080805","type":"SUPPL","sponsor":"BAUSCH AND LOMB","applicationNumber":"NDA021737"},{"date":"20110602","type":"SUPPL","sponsor":"BAUSCH AND LOMB","applicationNumber":"NDA021737"},{"date":"20240528","type":"SUPPL","sponsor":"PH HEALTH","applicationNumber":"ANDA040256"},{"date":"20020712","type":"ORIG","sponsor":"PH HEALTH","applicationNumber":"ANDA040256"},{"date":"20080116","type":"SUPPL","sponsor":"PH HEALTH","applicationNumber":"ANDA040256"},{"date":"20031120","type":"SUPPL","sponsor":"PH HEALTH","applicationNumber":"ANDA040256"},{"date":"20240528","type":"SUPPL","sponsor":"PH HEALTH","applicationNumber":"ANDA040256"},{"date":"20240605","type":"SUPPL","sponsor":"PH HEALTH","applicationNumber":"ANDA040256"}],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"NOVA63035 \"Corticosteroid\"","genericName":"NOVA63035 \"Corticosteroid\"","companyName":"Santen SAS","companyId":"santen-sas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NOVA63035 is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors. Used for Inflammatory eye conditions (presumed, based on Santen's focus).","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"supplemented","approval_date":"2002-07-12T00:00:00.000Z","mah":"PH HEALTH","brand_name_local":null,"application_number":"ANDA040256"},{"country_code":"US","regulator":"FDA","status":"supplemented","approval_date":"2005-04-08T00:00:00.000Z","mah":"BAUSCH AND LOMB","brand_name_local":null,"application_number":"NDA021737"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-04-25T00:00:00.000Z","mah":"RISING","brand_name_local":null,"application_number":"ANDA090982"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-11-20T00:00:00.000Z","mah":"CADILA","brand_name_local":null,"application_number":"ANDA210198"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-10-17T00:00:00.000Z","mah":"ALEMBIC","brand_name_local":null,"application_number":"ANDA218601"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}